The customer for this injector pen is a leader in the development and manufacturing of delivery systems for drug self-administration.

The pens are produced in the company’s China facility for use in China and other Asian markets. The completion of the commercialization of this project represents the cornerstone of the company’s recently announced "China for China" strategy.

This project, which was started in 2011, included a global engineering team, led from Europe, that has successfully transferred this product into production. The program features molds built in Europe and China, and an automated on-line scalable process, which produces a finished injector pen.

Phillips-Medisize president and CEO Matt Jennings noted that the start of production signifies the successful execution of its China for China strategy.

"The global Phillips-Medisize team is very excited about the attainment of this milestone, as it validates our fully-integrated capabilities for customers that desire products designed specifically for the China/Asia market and manufactured in a Chinese facility, all with stateof-the-art western medical quality systems and procedures," Jennings added.

Phillips-Medisize China is located in the Suzhou Industrial Park (SIP), and is ISO 13485 and CFDA registered.

In addition to medical device, disposable diagnostics components, and drug delivery device manufacturing, Phillips-Medisize will also be opening a Design Development Center in Suzhou later this year. Other investments in the facility planned for 2014 include expanded office space, added molding capacity, and upgrades to mold repair and maintenance capabilities.